Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).-MedSci.cn

Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).

Kucuk, O; Smith, C; Plasse, T; Ogretmen, B; Mehrotra, S; Gourdin, TS; Bilen, MA; Carthon, BC; Nazha, B; Goldman, J; Lilly, MB

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6):

科室
- - 订阅+
  - 更多科室
工具
服务